CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Nasopharyngeal swabsWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug384 Blood samples (collection of 5 mL of blood in a dry tube) Wiki 1.00

Correlated MeSH Terms (3)


Name (Synonyms) Correlation
D003866 Depressive Disorder NIH 0.24
D001008 Anxiety Disorders NIH 0.17
D003863 Depression, NIH 0.15

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0000716 Depressivity HPO 0.24

There is one clinical trial.

Clinical Trials


1 COVID-19 Study of the Serological Response Against the SARS-CoV-2 Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur

This research proposes to study a large healthy population active for the presence of antibodies directed against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus and this over time. After verification of the inclusion criteria and information by the coordinating investigative doctor, the volunteers sign a written consent. A nurse will take blood samples under safe conditions compatible with the pandemic period and while respecting the protection of the volunteer's personal data. The blood samples will be taken at 3 times: T0 (day of inclusion), between 6 weeks and 3 months and 6 months' post-inclusion. Each blood sample consists of a collection of 5 mL of blood in a dry tube. The serum samples will be extracted and collected prospectively from the blood samples. A questionnaire will be completed by the inclusion volunteer (T0) in the study then 1, between 6 weeks and 3 months and 6 months' post-inclusion. The nasopharyngeal swabs will be performed at 2 times: between 6 weeks and 3 months and 6 months post-inclusion for Institut Curie staff who have had at least one of the following three criteria on the sample or questionnaire carried out at T0: - have had RT-PCR+ - and/or presence of antibodies at the 95% threshold - and/or anosmia/ageusia - and/or digestive syndrome with associated respiratory signs. In case of infection between sampling times, if the volunteer meets one of the three criteria above, a nasopharyngeal swab will be performed during the following visits. The nasopharyngeal swab shall also be proposed to volunteers not meeting the 4 above listed criteria in order to have a control group (about 100 volunteers) for future statistical analyses. If the volunteers accept, naso-pharyngeal swab shall be performed between 6 weeks and 3 months and 6 months after inclusion. The nasopharyngeal swabs will be performed at 3 times for Institute Pasteur personnel: at T0 (inclusion day), between 6 weeks and 3 months, and 6 months post-inclusion

NCT04369066 Volunteers From the Institute Curie and Institute Pasteur Staff Who Are Not Showing Active SARS-CoV-2 Infection Diagnostic Test: Blood samples (collection of 5 mL of blood in a dry tube) Diagnostic Test: Nasopharyngeal swabs

Primary Outcomes

Description: Detection of antibodies against the SARS-CoV-2 virus with serological tests

Measure: Antibodies against the SARS-CoV-2 virus in serum at inclusion

Time: 1 day

Description: Detection of antibodies against the SARS-CoV-2 virus with serological tests

Measure: Antibodies against the SARS-CoV-2 virus in serum at 1 month

Time: 1 month

Description: Detection of antibodies against the SARS-CoV-2 virus with serological tests

Measure: Antibodies against the SARS-CoV-2 virus in serum at 3 months

Time: 3 months

Description: Detection of antibodies against the SARS-CoV-2 virus with serological tests

Measure: Antibodies against the SARS-CoV-2 virus in serum at 6 months

Time: 6 months

Secondary Outcomes

Description: Comparative performance of anti-SARS-CoV-2 antibody detection techniques (sensitivity and specificity of serological tests)

Measure: Comparative performance of anti-SARS-CoV-2 antibody detection techniques

Time: 9 months

Description: Prevalence of immune subjects for SARS-CoV-2 in a well-defined active healthy population, working at the hospital or not, leading to variable exposure levels

Measure: Prevalence of immune subjects for SARS-CoV-2

Time: 3 months

Description: Nature and quantity of anti-SARS-CoV-2 antibodies: ImmunoglobulinM, ImmunoglobulinG and ImmunoglobulinA)

Measure: Nature and quantity of anti-SARS-CoV-2 antibodies

Time: 3 months

Description: The analysis of the evolution of serology results over time will be done by a mixed model taking into account the repeated framework of the data of a subject

Measure: Evolution of the different antibodies against the SARS-CoV-2 virus over time.

Time: 6 months

Description: Prevalence of Anti-covid IgA in volonteers RT/PCR+ and/or presence of antibodies at the 95 % threshold and/or COVID symptoms

Measure: Prevalence of Anti-covid IgA response in the nasal mucosa

Time: 6 months


No related HPO nodes (Using clinical trials)